Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03607604
• Other study ID #: IREC018
• Status: Active, not recruiting
• Start date: April 1, 2015
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2020
• Source: Imperial College London Diabetes Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims to investigate the validity of 2 hour post-prandial UCPCR test in paediatric and adult patients with diabetes duration greater than 2 and 5 years, respectively, for the purposes of distinguishing between patients with type 1 diabetes and MODY in the UAE population.

Description:

Urinary C-peptide creatinine ratio (UCPCR) is a non invasive measure of endogenous insulin secretion and has been shown to be effective in identifying Maturity Onset Diabetes of the Young (MODY) from Type 1 Diabetes in adults and paediatric population. Here in the UAE, diabetes prevalence is at 18.9% of the general population and patients are medically treated according to their diabetes type. Currently identification of patients with MODY poses multiple challenges and in some instances results in wrongful diagnosis and treatment of the patients. Most commonly, patients are treated as having type 1 diabetes and given unnecessary insulin injections.

Making correct diabetes diagnosis is pivotal for appropriate disease management. Currently, a set of criteria including age of onset of diabetes (<30 years), BMI<25kg/m2 and absence of islet-cell and GAD auto-antibodies are applied in order to identify potential Maturity Onset Diabetes of the Young (MODY) patients. This has to be followed by genetic testing before final diagnosis is made. Although the set criteria increase the probability of identifying MODY patients, fully discriminating between MODY and type 1 diabetes can still be difficult. As such, some MODY patients (e.g. with mutations in HNF1A or HNF4A genes) are wrongfully treated with insulin when sulphonylureas would be efficient enough for management of their diabetes.

This study will consists of three groups; patients who are autoantibody negative (divided into patients with potential MODY and patients with type 2 diabetes), patients diagnosed with type 1 diabetes and patients who do not have diabetes at the time of recruitment (selected randomly and will include patients with other diagnoses such as IFG and/or IGT). All groups will consist of paediatric patients (≤18 years of age) and adult patients (age of onset of diabetes ≤ 30 years).

The scientific aims of the study are:

• Validating UCPCR as an in-house test that can potentially be used for clinical purposes.

• Measuring UCPCR in the study cohort and testing if a cutoff of 0.7nmol/mmol in children and 0.2nmol/mmol in adults will apply to population of interest (ie UAE population).

• Using operating characteristic curves to identify the optimal UCPCR cut-off for discriminating diabetes subtypes in.

• Confirming the UCPCR results through genetic analysis of the samples.

• Validating positive genetic test results by performing mutational analysis on the parents of the patient.

• Potentially identifying novel MODY mutations in the study population.

• conducting UCPCR measurements for patients who have been clinically and genetically diagnosed with MODY. This will assist the investigators in confirming the cutoff values for MODY diagnosis.

• Successfully estimating the background prevalence of MODY in diabetes patients in the Emirates of Abu Dhabi.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 778
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients with age and age of diabetes onset of <18 years

• patients with age of =18 years and age of diabetes onset of =30 years

Exclusion Criteria:

• patients with age of =18 years and age of diabetes onset of >30 years

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2
• Maturity-onset Diabetes of the Young

Intervention

Genetic:
• Next generation sequencing (NGS)
Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.

Locations

Country	Name	City	State
United Arab Emirates	Imperial College London Diabetes Centre	Abu Dhabi

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London Diabetes Centre

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary C-peptide Creatinine Ratio (UCPCR)	Measuring UCPCR in our study cohort and testing if a cutoff of 0.7nmol/mmol in children and 0.2nmol/mmol in adults will apply to our population of interest (ie UAE population).	2 hours post-prandial
Secondary	Receiver operating characteristic (ROC) curve	Using receiver operating characteristic (ROC) curves to identify the optimal UCPCR cut-off for discriminating diabetes subtypes in our study population.	through study completion, an average of 1 year
Secondary	Genetic analysis	Confirming our UCPCR results through genetic analysis of the samples.	through study completion, an average of 2 year
Secondary	Positive genetic result analysis	Validating positive genetic test results by performing mutational analysis on the parents of the patient.	through study completion, an average of 2 year
Secondary	Novel MODY genes and mutations	Identifying novel MODY genes and/or mutations in the study population through next generation sequencing methodologies	through study completion, an average of 2 year
Secondary	UCPCR measurements	Conducting UCPCR measurements for patients who have been clinically and genetically diagnosed with MODY. This will assist us in confirming the cutoff values for MODY diagnosis.	through study completion, an average of 2 year
Secondary	Prevalence of MODY	Estimating the background prevalence of MODY in diabetes patients in the Emirates of Abu Dhabi.	through study completion, an average of 2 year